GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Afamelanotide acetate overview

Afamelanotide (Scenesse) is an analog of the peptide hormone alpha-melanocyte stimulating hormone (alpha-MSH) that tends to induce skin tanning. It is formulated as Implant administered through subcutaneous route. Scenesse is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).

Afamelanotide acetate is under development for the treatment of vitiligo, acute arterial ischaemic stroke (AIS), erythropoietic protoporphyria, variegate porphyria related skin disease, Parkinson's disease and xeroderma pigmentosum (genetic disorder). It was also under development for chronic urticaria, actinic (solar) keratosis, squamous cell carcinoma, Hailey-Hailey disease (benign familial pemphigus), polymorphous light eruption and unspecified dermatological disorders.

It was also under development for the treatment of moderate acne vulgaris.

Clinuvel Pharmaceuticals overview

Clinuvel Pharmaceuticals (Clinuvel) is a global specialty pharmaceutical company. The company’s primary focus is on the development and commercialization of treatments for patients with genetic, metabolic, systemic, and life-threatening acute disorders, as well as healthcare solutions for the general population. Its lead product, Scenesse (afamelanotide), is a systemic photoprotective drug used for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s products are primarily used by patient populations requiring systemic photoprotection, DNA repair, repigmentation, and treatment for acute or life-threatening conditions. It operates in various regions including Europe, the US, Israel, and Australia. Clinuvel is headquartered in Victoria, Melbourne, Australia.

For a complete picture of Afamelanotide acetate’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.